Ami Shah who is the Co-Director of the Johns Hopkins Scleroderma Center discusses the findings related to her study on scleroderma and cancer.
Yeah, yeah. So we are studying a disease known as square derma, which is a complex autoimmune disease that can cause excessive skin thickening and affect internal organs in the body. It's long been recognized that patients with scleroderma have an increased risk of cancer. And we've identified that there are subgroups of scleroderma patients who have a high risk of cancer. Around the time that scleroderma is developing, we've been able to identify that distinct autoantibodies can identify these patients who are at high risk of cancer um and uh that they may have cancer as a trigger for the development of their square derma. Mm hmm. Yeah, auto antibodies could be very powerful tools for risk stratification for cancer. And it may inform the approach to cancer detection that we should be taking in a given patient. As distinct types may be enriched in patients with unique autoantibodies. An important question from this work, as if we identify the cancer in a patient with new onset scleroderma, could cancer therapy be effective scleroderma therapy? Mm
Facebook
Twitter
YouTube
LinkedIn
Instagram
E-News
BROADCASTMED